The phrase “long-lasting effect” needs a timeline. Repeated observations while treatment continues answer a different question from observations after it has stopped. Primary study
What was reported
The experiment used 24 Wistar rats selected for high initial emotional reactivity. It compared TP-7, the tuftsin-derived heptapeptide associated with Selank, with passive and injection controls. Anxiety-related behavioral effects were reported from the second day and across four weeks of repeated administration. The peptide did not itself change body mass in this experiment. Primary report
Our appraisal: selection, repeated testing, and the meaning of duration
Selecting animals for high initial reactivity defines a particular experimental population. That can make a model sensitive to a behavioral intervention, but it also limits what the result says about unselected animals or different baseline states. It should not be translated directly into a claim about every form of human anxiety.
Repeated behavioral testing introduces its own interpretive questions. Familiarity with the apparatus, handling, and prior testing can influence later responses. Appropriate controls help separate these influences from an intervention effect; they do not make the testing history irrelevant.
The treatment timeline is central. A response observed repeatedly during administration may indicate maintained activity under that schedule. It does not establish how long the response survives after withdrawal, whether tolerance eventually develops, or what a much longer exposure would do.
Body mass is one safety-related observation, not a comprehensive safety assessment. No detected weight effect cannot exclude neurological, organ-specific, or delayed adverse effects that were not adequately examined.
The study offers an on-treatment behavioral signal in selected rats. A careful account preserves that scope instead of advertising a lasting human benefit or a broad absence of adverse effects.
Frequently asked questions
How many rats were used?
Were they selected for high initial reactivity?
Yes.
Were control groups included?
Yes, passive and injection controls.
Did observations extend across four weeks?
Yes, during repeated administration.
Does that prove four weeks of benefit after stopping?
No.
Was body mass changed by the peptide itself?
Not in the reported experiment.
Is unchanged body mass comprehensive safety evidence?
No.